Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Terre

Interventional Cardiology New Orleans, LA Medical Doctor

NPI 1407234776 CMS profile 1341269

1415 Tulane Ave Fl 4, New Orleans, LA 70112

Open in the dashboard

General payments

$10,333

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juan Terre of New Orleans, LA is reported in the CMS Open Payments database as having received $10,333 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,653 19
2024 General $424 3
2023 General $1,081 14
2022 General $3,088 33
2021 General $312 5
2020 General $172 3
2019 General $2,604 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Terre
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Juan Terre were reported at $2,653. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Juan Terre Interventional Cardiology median Middle half National median
2019 $2,604 $1,097 $329–$3,048 $163
2020 $172 $473 $161–$1,480 $114
2021 $312 $677 $233–$1,827 $132
2022 $3,088 $978 $333–$2,724 $149
2023 $1,081 $1,136 $382–$2,986 $160
2024 $424 $1,181 $395–$3,326 $164
2025 $2,653 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,710 20 payments
  2. Edwards Lifesciences Corporation $2,047 18 payments
  3. Medtronic Vascular, Inc. $1,668 19 payments
  4. Abbott Laboratories $1,123 13 payments
  5. Abiomed $462 4 payments
  6. Medtronic, Inc. $421 4 payments
  7. W. L. Gore & Associates, Inc. $319 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $311 3 payments
  9. Penumbra, Inc. $170 3 payments
  10. Amgen Inc. $148 3 payments
  11. Other $953 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,734 98 payments
  2. Travel and Lodging $2,501 9 payments
  3. Grant $89 1 payment
  4. Education $9 1 payment
Products named General payments · program years 2019–2025
  1. EkoSonic $1,609 7 payments
  2. Resolute $1,066 9 payments
  3. MITRACLIP $857 9 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $700 4 payments
  5. Impella $462 4 payments
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $453 3 payments
  7. CoreValve Evolut $375 6 payments
  8. Carto 3 $365 3 payments
  9. JARDIANCE $311 3 payments
  10. SYNERGY $216 2 payments
  11. Other $3,745 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

127

Median for Interventional Cardiology: 2,236

Drug cost

$1,063

Median for Interventional Cardiology: $380,412

Branded share of claims

26.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 30 $308
Nitroglycerin Generic 12 $227
Ezetimibe Generic 11 $223
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 20 $198
Atorvastatin Calcium Generic 24 $45
Clopidogrel Clopidogrel Bisulfate Brand 14 $31
Spironolactone Generic 16 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$26,382

Medicare's payments for the services billed

Medicare patients

66

Average age 70

Services billed

253

33 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 73%
Ischemic heart disease 67%
Chronic kidney disease 61%
Diabetes 59%
Atrial fibrillation 36%
Arthritis 33%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record